Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Phase I study of BRD4 inhibitor SYHA-1801 begins for advanced solid tumors

May 12, 2020

Enrollment underway for first-in-human study of BRAF inhibitor ABM-1310 in advanced solid tumors

May 12, 2020

Dual adenosine A2A/A2B receptor antagonists described by Merck KGaA

May 12, 2020

Wild-type and mutant RET inhibitors identified at Medshine Discovery

May 12, 2020

Dana-Farber Cancer Institute, Voronoi patent wild-type and mutant LRRK2 inhibitors

May 12, 2020

New histone-lysine N-methyltransferase SMYD3 inhibitors identified at Epizyme

May 12, 2020

Array BioPharma discloses new PTPN11 inhibitors

May 12, 2020

Novel peptide-targeted approach improves potency of anticancer drugs

May 12, 2020

FDA approves Lynparza with bevacizumab for HRD-positive advanced ovarian cancer

May 11, 2020

Oncoinvent recruits for phase I study of Radspherin

May 11, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...